𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Phase I study of liposomal annamycin

✍ Scribed by Daniel J. Booser; Roman Perez-Soler; Paul Cossum; Laura Esparza-Guerra; Qing-Ping Wu; Yiyu Zou; Waldemar Priebe; Gabriel N. Hortobagyi


Publisher
Springer
Year
2000
Tongue
English
Weight
98 KB
Volume
46
Category
Article
ISSN
0344-5704

No coin nor oath required. For personal study only.


πŸ“œ SIMILAR VOLUMES


Phase I study of pegylated liposomal dox
✍ Paula M. Fracasso; Kristie A. Blum; Benjamin R. Tan; Carole L. Fears; Nancy L. B πŸ“‚ Article πŸ“… 2002 πŸ› John Wiley and Sons 🌐 English βš– 71 KB πŸ‘ 2 views

## Abstract ## BACKGROUND Pegylated liposomal doxorubicin (PEG‐LD) and gemcitabine have single‐agent activity in breast and ovarian carcinoma patients. We conducted a Phase I trial to evaluate the maximum tolerated dose (MTD) and toxicities of this combination in patients with advanced malignancie

Phase I dose and sequencing study of peg
✍ Paula M. Fracasso; Luis C. Rodriguez; Thomas J. Herzog; Carole L. Fears; Sherry πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 89 KB πŸ‘ 1 views

## Abstract ## BACKGROUND Pegylated liposomal doxorubicin (PEG‐LD) and docetaxel have single‐agent activity in several malignancies. The authors conducted a Phase I trial to evaluate the maximum tolerated dose (MTD), toxicities, and effect of dose sequencing of this combination in patients with ad